Clinical Trial Update: Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of sulfatinib for advanced medullary thyroid carcinoma and iodine-refractory differentiated thyroid carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Medullary Thyroid Carcinoma
• Thyroid Carcinoma

Drugs mentioned

• Sulfatinib (sulfatinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Thyroid Carcinoma | Phase 2 | Status: COMPLETED